VasQ and A
The FDA has approved VasQ, a new device to reduce fistula failure, for a 2-year clinical trial with 129 patients. The device keeps fistulas from growing too large by providing an external support.
Read the full article » | Posted 08-17-2017
Related Articles
- Xeltis is Trialing its Polymer-based Vascular Access Posted 03-12-2026
- New Bluetooth-enabled CAPD System Enhanced Patient Satisfaction Posted 03-12-2026
- Emerging Biomarker Research in PD Posted 03-12-2026
- Byonyks’ X1 APD Cycler Received FDA 510(k) Approval Last Summer Posted 02-17-2026